Shots:
The Chinese NMPA has approved neffy 2mg for the emergency treatment of type I allergic reactions (anaphylaxis) in adults & children (≥30kg), with availability anticipated in the spring of 2026. Filing for neffy 1mg for children (15 to <30kg) to the NMPA is expected in the coming mos.
In 2021, ARS Pharma licensed neffy…
Shots:
Inconsistent access to epinephrine auto-injectors continues to be a major unmet need in the management of anaphylaxisÂ
neffy, an innovative intranasal epinephrine spray, provides a needle-free alternative for the emergency treatment of severe allergic reactions, including anaphylaxis, in adults and children aged four years and older who weigh at least 33 lbsÂ
Richard Lowenthal,…

